6.18
Precedente Chiudi:
$6.53
Aprire:
$6.17
Volume 24 ore:
43,278
Relative Volume:
0.46
Capitalizzazione di mercato:
$95.50M
Reddito:
-
Utile/perdita netta:
$-14.88M
Rapporto P/E:
-6.3061
EPS:
-0.98
Flusso di cassa netto:
$-10.29M
1 W Prestazione:
+17.49%
1M Prestazione:
-5.65%
6M Prestazione:
-31.03%
1 anno Prestazione:
-26.69%
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Confronta COYA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
COYA
Coya Therapeutics Inc
|
6.18 | 95.50M | 0 | -14.88M | -10.29M | -0.98 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-04 | Iniziato | D. Boral Capital | Buy |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
(COYA) Long Term Investment Analysis - news.stocktradersdaily.com
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia
Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe
GMP Production of Exosomes Slated for Later This Year - streetwisereports.com
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World
Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports
What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo
Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa
Coya Therapeutics advances Treg exosome production - Investing.com India
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe
Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
(COYA) Trading Report - news.stocktradersdaily.com
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. - Business Wire
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Coya Therapeutics, Inc. SEC 10-K Report - TradingView
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering - Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement - Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Where are the Opportunities in (COYA) - Stock Traders Daily
Coya Therapeutics (COYA) to Release Earnings on Tuesday - Defense World
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - The AM Reporter
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Market Watch Highlights: Coya Therapeutics Inc (COYA) Ends on an Upturn Note at 6.88 - The Dwinnex
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):